[Side-effects of cytostatic therapy with special reference to potential carcinogenic effects].
D000477:Alkylating Agents / Q000009:adverse effects; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000963:Antimetabolites / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002066:Busulfan / Q000009:adverse effects; D005472:Fluorouracil / Q000009:adverse effects; D006394:Hemangiosarcoma / Q000139:chemically induced; D015122:Mercaptopurine / Q000009:adverse effects; D008937:Mitomycins / Q000009:adverse effects; D009369:Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000139:chemically induced; D011033:Podophyllin / Q000009:adverse effects; D051381:Rats; D012513:Sarcoma, Experimental / Q000139:chemically induced; D013852:Thiotepa / Q000009:adverse effects; D014747:Vinblastine / Q000009:adverse effects
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D008937:Mitomycins; D014747:Vinblastine; D011033:Podophyllin; D013852:Thiotepa; D015122:Mercaptopurine; D002066:Busulfan; D005472:Fluorouracil
Nebenwirkungen cytostatischer therapie unter besonderer Berücksichtigung potentieller carcinogener Wirkungen.